The company will report its earnings for FY 2018 on 03/08/2019. Generally, the company reports earnings better than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have not revised their EPS estimates.
Annual earnings per share is expected at 3.32 CHF for 2018 (+ 7.6% from 2017). A summary of annual publications and estimates is available below.
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
BACHEM HOLDING AG 
